13313-18-3

Usage

InChI:InChI=1/C12H9N3O3/c16-12(14-10-2-1-7-13-8-10)9-3-5-11(6-4-9)15(17)18/h1-8H,(H,14,16)

Upstream product

• 462-08-8 pyridin-3-ylamine 
• 122-04-3 4-nitro-benzoyl chloride 
• 62-23-7 4-nitro-benzoic acid 
• 504-29-0 2-aminopyridine 

Downstream Products

• 13160-59-3 4-amino-N-pyridin-3-yl-benzamide 

Relevant academic research and scientific papers

Colorimetric 'naked-eye' sensor for anions based on conformational flexible tripodal receptor

A new tripodal receptor for anion sensing based on amide-pyridinium as recognition site and nitro-benzene as signaling unit was designed and successfully synthesized. This receptor showed high selectivity and strong binding affinity toward AcO-

Spectroscopic and Crystallographic Characterization of the R3N+?C?H???X Interaction

As appreciation for nonclassical hydrogen bonds has progressively increased, so have efforts to characterize these interesting interactions. Whereas several kinds of C?H hydrogen bonds have been well-studied, much less is known about the R3Nsu

N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)

A series of 23 N-(Pyridin-3-yl)benzamides was synthesized and evaluated for their potential to inhibit human steroid-11β-hydroxylase (CYP11B1) and human aldosterone synthase (CYP11B2). The most potent and selective CYP11B2 inhibitors (IC50 valu

Exploration of secondary and tertiary pharmacophores in unsymmetrical N,N′-diaryl urea inhibitors of soluble epoxide hydrolase

The impact of various secondary and tertiary pharmacophores on in vitro potency of soluble epoxide hydrolase (sEH) inhibitors based on the unsymmetrical urea scaffold 1 is discussed. N,N′-Diaryl urea inhibitors of soluble epoxide hydrolase exhibit subtle variations in inhibitory potency depending on the secondary pharmacophore but tolerate considerable structural variation in the second linker/tertiary pharmacophore fragment.

Substituted cyclic amine compound, production process thereof and pharmaceutical composition for circulatory organ use containing the same

A substituted cyclic amine compound represented by the following general formula (1) STR1 wherein each of R1 to R5 represents a hydrogen atom, a halogen atom, a lower alkyl group, a lower alkoxy group or the like, A represents a carbonyl group or a sulfonyl group, B represents a methine moiety or a nitrogen atom, D represents a methine moiety, a nitrogen atom or =N(→O)-- and n is an integer of 2 to 3; and synthetic methods thereof. The inventive compound is useful in preventing and treating circulatory organ-related diseases such as hypertension, ischemic heart disease, cerebrovascular disease, peripheral circulatory disease and the like.

Towards the development of non-enediyne approaches for mimicking enediyne chemistry: Design, synthesis and activity of a 1,4-bisdiazonium compound

1,4-bisdiazonium compounds, whichmay be precursors of aryl 1,4-diradicals, have the potential to mimic the DNA cleaving activity of the enediyne antibiotics. To this end, the ability to generate and activate 1,4-bisdiazonium compounds in good yield (e.g.,